Owlet has collaborated with Rhapsody for secure integration of infant health data from prescription pulse oximeter, BabySat, directly into existing electronic health record (EHR) systems.
Owlet’s BabySat has received clearance from the US Food and Drug Administration (FDA).
The integration establishes a secure, standards‑based route for the flow of Owlet’s paediatric data into provider environments, allowing clinicians to record and view key information as part of routine documentation.
Through Rhapsody’s adaptable integration, organisations can minimise custom development, decrease errors, and guarantee timely, accurate patient information reaches care teams at the point of need.
Owlet president and CEO Jonathan Harris said: “Our partnership with Rhapsody is another step forward in Owlet’s mission to redefine how infant data is integrated and used more effectively within the healthcare system.
“We’re connecting the dots between home and hospital by delivering clinically validated infant monitoring that keeps parents and providers connected from anywhere. By integrating with the Rhapsody trusted exchange platform, we’ve made sharing infant health data simple, empowering families to make informed decisions and allowing clinicians to deliver better care.”
The partnership simplifies home and clinical settings connectivity and supports hospitals in scaling paediatric remote patient monitoring (RPM) programmes.
Clinicians will be able to access real‑time, continuous information from home‑based patients, integrated into existing tools.
Rhapsody CEO Sagnik Bhattacharya said: “True interoperability isn’t just about moving data, it’s about making that data meaningful in the moments that matter.
“By connecting Owlet’s clinically‑validated monitoring data directly into the EHR, we’re giving clinicians a fuller view of their youngest patients, and helping families feel more connected to their child’s care team.”
This integration represents a significant milestone in Owlet's expansion into clinical environments.
